BerGenBio

Legal Proceedings Report • Jun 18, 2018

BerGenBio: Posters presented at Congress of European Hematology Association (EHA)

Bergen, Norway, 18 June 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators presented interim data from its Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, in acute myeloid leukaemia (AML) and myeloid dysplastic syndrome (MDS) as well as biomarker data at the 23rd Congress of the European Hematology Association (EHA) in Stockholm (14-17 June 2018).

The Company's academic collaborators at the University of Bergen, Haukeland University Hospital (Bergen) presented a preclinical study investigating the involvement of AXL in mantle cell lymphoma (MCL), and of bemcentinib to be a potential new treatment option for this aggressive form of non-Hodgkin's lymphoma (NHL).

For more information please see https://ehaweb.org and the Company's website: https://www.bergenbio.com/investors/presentations/

Contacts

Richard Godfrey CEO, BerGenBio ASA +47 917 86 304

Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.